1st Quarter - Report

NOVARTIS for NOVARTIS

Firm
Client
Income
—
Expenses
$4,000,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

ACA Pharmaceutical Industry Fee Exclusions Anti-Inversion Tax Medical Device Tax Repeal & Suspension Section 385 Tax Regulation Tax Reform Orphan Drug Tax Tax Reform Border Adjustment Tax

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
SHAWN O'NEAIL —
CANDICE PHIPPS —

Contacted: Centers For Medicare and Medicaid Services (CMS); Veterans Affairs, Dept of (VA); U.S. Agency for International Development (USAID); State, Dept of (DOS); White House Office; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); SENATE; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Commerce, Dept of (DOC)

Veterans VET

Veterans Affairs National Pharmaceutical Bid

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —

Contacted: U.S. Trade Representative (USTR); Food & Drug Administration (FDA); U.S. Agency for International Development (USAID); Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); White House Office; Veterans Affairs, Dept of (VA); SENATE; State, Dept of (DOS); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Trade (domestic/foreign) TRD

Free Trade Agreements: - Intellectual Property and Transparency Provisions - Free Trade Agreements Access to Medicines Issues Global Health Issues India, China and Canada IP and market Access Issues Trans-Pacific Partnership FTA Sub-standards Medicines Quality of Medicines . Trade Promotion Authority . Trans-pacific Partnership . Trans Atlantic Trade and Investment Partnership International Market Access and Intellectual Property Issues Biopharmaceutical Innovation Policies Colombia Intellectual Property Regulatory Cooperation The North American Free Trade Agreement - NAFTA USTR Special 301 Report/National Trade Estimate

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
SARAH HALLER —
SHAWN O'NEAIL —
CANDICE PHIPPS —

Contacted: Commerce, Dept of (DOC); Veterans Affairs, Dept of (VA); Health & Human Services, Dept of (HHS); State, Dept of (DOS); SENATE; Food & Drug Administration (FDA); White House Office; Office of Management & Budget (OMB); U.S. Agency for International Development (USAID); U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

Data Exclusivity Trade Secrets Intellectual Property Biopharmaceutical Innovation Policy Issues Biologics Data Protection Issues Patient Litigation Reform and Issues Related to Post Grant Proceedings at PTO Neonates BPCIA Hatch-Waxman Patents

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
SHAWN O'NEAIL —
CANDICE PHIPPS —

Contacted: U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); U.S. Agency for International Development (USAID); Centers For Medicare and Medicaid Services (CMS); SENATE; Commerce, Dept of (DOC); White House Office; HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); State, Dept of (DOS)

Health Issues HCR

Cell & Gene Therapy Personalized Medicine Section 9008 of Patient Protection and Affordable Care Act FSA/HSA - Support reinstating coverage of OTC products 340B Drug Discount Program Dual Eligibles Program DQSA Implementation (Track & Trace) Certified Importer Program MDUFA (Medical Device User Fee Act) Implementation Drug Importation Reimbursement for medical devices GMP related to manufacturing sites Biosimilars PDUFA Low-income Subsidy in Part D REMS Creates Act FCLCA Value of Medicines Drug Cost/Pricing Biosimilars Reimbursement Generic Drugs Medicaid FDA Regulations of Lab Developed Tests (LDT) Reimbursement for LDTs Part B Demo IPAB Generic Drug Labeling Outcomes-based Contracting Expanded Access PREA/BPCA BSUFA GDUFA Truthful, Non-Misleading Drug Information Part D Non-interference S.469 - Affordable and Safe Prescription Drug Importation Act Orphan Drugs Drug Pricing Transparency S.456 - RACE for Children Act S.204 - Trickett Wendler Right to Try Act of 2017

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
SARAH HALLER —
SHAWN O'NEAIL —
CANDICE PHIPPS —
WENDY P SUSSMAN —

Contacted: HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Office of Management & Budget (OMB); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); U.S. Agency for International Development (USAID); SENATE; Centers For Medicare and Medicaid Services (CMS); White House Office; Commerce, Dept of (DOC); Food & Drug Administration (FDA); Veterans Affairs, Dept of (VA)

Bills named: S. 469 (115th), S. 456 (115th), S. 204 (115th)

Medicare/Medicaid MMM

Biosimilars Medicare Part D Drug Pricing Part B CMMI Part B Demonstration Project Generics Innovative Pharmaceuticals

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
SHAWN O'NEAIL —
CANDICE PHIPPS —
WENDY P SUSSMAN —

Contacted: U.S. Agency for International Development (USAID); Commerce, Dept of (DOC); State, Dept of (DOS); White House Office; Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE; Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA)

Budget/Appropriations BUD

FDA Appropriations funding for Generic Drugs Certified Importer Program (CIP) FY 2017 Labor HHS Appropriations Bill Reconciliation Gx Drug Labeling Biosimilars

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
SHAWN O'NEAIL —
CANDICE PHIPPS —
WENDY P SUSSMAN —

Contacted: Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); State, Dept of (DOS); U.S. Trade Representative (USTR); U.S. Agency for International Development (USAID); Veterans Affairs, Dept of (VA); Centers For Medicare and Medicaid Services (CMS); SENATE; White House Office; Office of Management & Budget (OMB)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.